000963 华东医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入22,066,6461.81%43,612,01041,905,70740,623,78337,714,587
减:营业总成本19,835,8832.15%39,388,88137,493,02037,081,91534,568,570
    其中:营业成本14,828,9343.50%29,499,47927,988,54727,461,73225,682,497
               财务费用15,815-29.47%18,77322,26551,19078,257
               资产减值损失(7,889)--(87,896)(41,006)(6,520)(3,822)
公允价值变动收益--------(13,756)28,469
投资收益596-100.89%(137,843)(129,191)(219,713)(141,560)
    其中:对联营企业和合营企业的投资收益28,392-180.28%(75,923)(68,453)(188,391)(115,619)
营业利润2,257,9760.65%4,107,8934,324,7373,452,9273,061,454
利润总额2,210,9930.81%4,016,4624,301,5143,465,9863,031,124
减:所得税费用371,104-4.80%605,616807,328619,589498,499
净利润1,839,8902.03%3,410,8473,494,1862,846,3972,532,626
减:非控股权益(20,868)81.49%(3,489)(17,919)7,53633,411
股东净利润1,860,7572.53%3,414,3353,512,1052,838,8612,499,214

市场价值指针
每股收益 (元) *1.0613.08%1.9482.0051.6221.428
每股派息 (元) *0.3500.00%0.9300.9300.5800.290
每股净资产 (元) *14.5077.13%14.14513.14511.99710.592
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容